Register
Better survival with modified FOLFIRINOX regimen for patients with pancreatic cancer |
Journal Updates
eMediNexus Coverage from: 
Better survival with modified FOLFIRINOX regimen for patients with pancreatic cancer

0 Read Comments                

In a 24-week study published December 20, 2018 in the New England Journal of Medicine, adjuvant therapy with a modified FOLFIRINOX regimen (oxaliplatin [85 mg/m2], irinotecan [180 mg/m2, reduced to 150 mg/m2 after a protocol-specified safety analysis], leucovorin [400 mg/m2], and fluorouracil [2400 mg/m2] every 2 weeks) led to significantly longer survival than gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) among patients with resected pancreatic cancer. At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group. However, incidence of toxic effects was higher in the modified-FOLFIRINOX group vs in the gemcitabine group.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now